Amgen Inc.

11/20/2026 | Press release | Distributed by Public on 11/20/2026 18:36

Initial Statement of Beneficial Ownership (Form 3)

FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Paulino Arleen
2. Date of Event Requiring Statement (Month/Day/Year)
11/16/2026
3. Issuer Name and Ticker or Trading Symbol
AMGEN INC [AMGN]
(Last) (First) (Middle)
ONE AMGEN CENTER DRIVE
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
EVP, Operations
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)
THOUSAND OAKS, CA 91320
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 4,455(1)(2) D
Common Stock 2,039.9774(3) I 401(k) Plan
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Nqso (Right to Buy) 05/05/2022(4) 05/05/2030 Common Stock 5,314 $236.36 D
Nqso (Right to Buy) 04/30/2023(5) 04/30/2031 Common Stock 5,434 $239.64 D
Nqso (Right to Buy) 08/06/2023(6) 08/06/2031 Common Stock 40,595 $230.15 D
Nqso (Right to Buy) 05/02/2024(7) 05/02/2032 Common Stock 7,070 $230.92 D
Nqso (Right to Buy) 05/02/2025(8) 05/02/2033 Common Stock 7,166 $235.97 D
Nqso (Right to Buy) 05/07/2026(9) 05/07/2034 Common Stock 4,326 $300.3 D
Nqso (Right to Buy) 05/06/2026(10) 05/06/2035 Common Stock 6,214 $270.44 D
Nqso (Right to Buy) 05/05/2027(11) 05/05/2036 Common Stock 5,146 $329.59 D

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Paulino Arleen
ONE AMGEN CENTER DRIVE
THOUSAND OAKS, CA 91320
EVP, Operations

Signatures

Andrea A. Robinson, attorney-in-fact for Ms. Paulino 11/20/2026
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) These shares include 2,181 Restricted Stock Units (RSUs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan). Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
(2) These shares include 66 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
(3) These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.
(4) 5,314 of these non-qualified stock options have vested and are exercisable.
(5) 5,434 of these non-qualified stock options have vested and are exercisable.
(6) 40,595 of these non-qualified stock options have vested and are exercisable.
(7) 7,070 of these non-qualified stock options have vested and are exercisable.
(8) 4,729 of these non-qualified stock options have vested and the remaining options will vest and become exercisable on 5/2/2027.
(9) 1,427 of these non-qualified stock options have vested and the remaining options will vest and become exercisable in two annual installments, commencing on 5/7/2027.
(10) 1,553 of these non-qualified stock options have vested and the remaining options will vest and become exercisable in three annual installments, commencing on 5/6/2027.
(11) These non-qualified stock options will vest and become exercisable in four equal annual installments of 25% each, commencing on 5/5/2027.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Amgen Inc. published this content on November 20, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 21, 2026 at 00:36 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]